Navigation

Researchers at UCD

John Crown

Newman Clinical Research Professor

School of Medicine
School Of Medicine
St Vincent's Hospital
Elm Park
Dublin 4

Tel:
Email:

Professional

         

Conference Contributions

Wilson, E., Crown, J; (2009) The effects of a diagnosis of early stage breast cancer (ESBC) on friendships. [Poster Presentation], British Psychosocial Oncology Conference, Cardiff , 03-DEC-09 - 04-DEC-09.
   

Education

Year 2007 Institution:
Qualification: MRCPI Subject:
Year 2007 Institution:
Qualification: BSc Subject:
Year 2007 Institution:
Qualification: MB Subject:
Year Institution:
Qualification: MB Subject:
Year Institution:
Qualification: BSc Subject:
Year Institution:
Qualification: MRCPI Subject:
         

Publications

     

Peer Reviewed Journals

Murtagh G, Lyons T;O'Connell E;Ballot J;Geraghty L;Fennelly D;Gullo G;Ledwidge M;Crown J;Gallagher J;Watson C;McDonald KM;Walshe JM (2016) 'Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up'. Breast Cancer Research and Treatment, 156 (3):501-506. [DOI] [Details]
Mullooly M, McGowan P;Crown J;Duffy MJ (2016) 'The ADAMs Family of Proteases as Targets for the Treatment of Cancer'. Cancer biology & therapy, . [DOI] [Details]
Bell T, Crown JP;Lang I;Bhattacharyya H;Zanotti G;Randolph S;Kim S;Huang X;Huang Bartlett C;Finn RS;Slamon D (2016) 'Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment'. Current Medical Research and Opinion, :1-7. [DOI] [Details]
Eustace AJ, Kennedy S;Larkin AM;Mahgoub T;Tryfonopoulos D;O'Driscoll L;Clynes M;Crown J;O'Donovan N (2015) 'Predictive biomarkers for dasatinib treatment in melanoma'. Oncoscience, 1 (2):158-166. [Details]
Mullooly M, McGowan PM;Kennedy SA;Madden SF;Crown J;O' Donovan N;Duffy MJ (2015) 'ADAM10: a new player in breast cancer progression?'. British Journal of Cancer, 113 (6):945-951. [DOI] [Details]
Mahgoub T, Eustace AJ;Collins DM;Walsh N;O'Donovan N;Crown J (2015) 'Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma'. International Journal of Oncology, 47 (3):900-908. [DOI] [Details]
Sonnenblick A, Francis PA;Azim HA;de Azambuja E;Nordenskj¿¿ld B;Guti¿¿rez J;Quinaux E;Mastropasqua MG;Ameye L;Anderson M;Lluch A;Gnant M;Goldhirsch A;Di Leo A;Barnadas A;Cortes-Funes H;Piccart M;Crown J (2015) 'Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer'. European journal of Cancer, 51 (12):1481-1489. [DOI] [Details]
Caiazza F, McGowan PM;Mullooly M;Murray A;Synnott N;O'Donovan N;Flanagan L;Tape CJ;Murphy G;Crown J;Duffy MJ (2015) 'Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells'. British Journal of Cancer, 112 (12):1895-1903. [DOI] [Details]
van den Hurk K, Balint B;Toomey S;O'Leary PC;Unwin L;Sheahan K;McDermott EW;Murphy I;van den Oord JJ;Rafferty M;FitzGerald DM;Moran J;Cummins R;MacEneaney O;Kay EW;O'Brien CP;Finn SP;Heffron CC;Murphy M;Yela R;Power DG;Regan PJ;McDermott CM;O'Keeffe A;Orosz Z;Donnellan PP;Crown JP;Hennessy BT;Gallagher WM (2015) 'High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients'. Melanoma Research, 25 (3):189-199. [DOI] [Details]
Stern HM, Gardner H;Burzykowski T;Elatre W;O'Brien C;Lackner MR;Pestano GA;Santiago A;Villalobos I;Eiermann W;Pienkowski T;Martin M;Robert N;Crown J;Nuciforo P;Bee V;Mackey J;Slamon DJ;Press MF (2015) 'PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance'. Clinical Cancer Research, 21 (9):2065-2074. [DOI] [Details]
Dowling P, Pollard D;Larkin A;Henry M;Meleady P;Gately K;O'Byrne K;Barr MP;Lynch V;Ballot J;Crown J;Moriarty M;O'Brien E;Morgan R;Clynes M (2015) 'Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer'. Molecular BioSystems, 11 (3):743-752. [DOI] [Details]
Duffy MJ, Walsh S;McDermott EW;Crown J (2015) 'Biomarkers in Breast Cancer: Where Are We and Where Are We Going?'. Advances in Clinical Chemistry, 71 :1-23. [DOI] [Details]
Elster N, Collins DM;Toomey S;Crown J;Eustace AJ;Hennessy BT (2015) 'HER2-family signalling mechanisms, clinical implications and targeting in breast cancer'. Breast Cancer Research and Treatment, 149 (1):5-15. [DOI] [Details]
Finn RS, Crown JP;Lang I;Boer K;Bondarenko IM;Kulyk SO;Ettl J;Patel R;Pinter T;Schmidt M;Shparyk Y;Thummala AR;Voytko NL;Fowst C;Huang X;Kim ST;Randolph S;Slamon DJ (2015) 'The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study'. Lancet Oncology, 16 (1):25-35. [DOI] [Details]
Duffy MJ, Crown J (2014) 'Monitoring response to therapy in patients with cancer: is circulating DNA the answer?'. Annals of Translational Medicine, 1 (3). [DOI] [Details]
Madden SF, Clarke C;Stordal B;Carey MS;Broaddus R;Gallagher WM;Crown J;Mills GB;Hennessy BT (2014) 'OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets'. Molecular Cancer, 13 . [DOI] [Details]
Gaule PB, Crown J;O'Donovan N;Duffy MJ (2014) 'cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?'. Expert Opinion on Therapeutic Targets, 18 (9):999-1009. [DOI] [Details]
Rani S, Corcoran C;Shiels L;Germano S;Breslin S;Madden S;McDermott MS;Browne BC;O'Donovan N;Crown J;Gogarty M;Byrne AT;O'Driscoll L (2014) 'Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors'. Cancer Research, 74 (14):3821-3833. [DOI] [Details]
McDermott MS, Browne BC;Conlon NT;O'Brien NA;Slamon DJ;Henry M;Meleady P;Clynes M;Dowling P;Crown J;O'Donovan N (2014) 'PP2A inhibition overcomes acquired resistance to HER2 targeted therapy'. Molecular Cancer, 13 . [DOI] [Details]
Corcoran C, Rani S;Breslin S;Gogarty M;Ghobrial IM;Crown J;O'Driscoll L (2014) 'miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer'. Molecular Cancer, 13 . [DOI] [Details]
Candon D, Healy J;Crown J (2014) 'Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer'. Acta Oncologica, 53 (2):201-208. [DOI] [Details]
McDermott M, Eustace AJ;Busschots S;Breen L;Crown J;Clynes M;O'Donovan N;Stordal B (2014) 'In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies'. Frontiers in Oncology, 4 . [DOI] [Details]
Rani S, Gately K;Crown J;O'Byrne K;O'Driscoll L (2014) 'Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma'. Cancer Biology and Therapy, 14 (12):1104-1112. [DOI] [Details]
Duffy MJ, Crown J (2013) 'Companion biomarkers: paving the pathway to personalized treatment for cancer'. Clinical Chemistry, 59 (10):1447-1456. [DOI] [Details]
Canonici A, Gijsen M;Mullooly M;Bennett R;Bouguern N;Pedersen K;O'Brien NA;Roxanis I;Li JL;Bridge E;Finn R;Siamon D;McGowan P;Duffy MJ;O'Donovan N;Crown J;Kong A (2013) 'Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer'. Oncotarget, 4 (10):1592-1605. [Details]
Crown JP, Di¿¿ras V;Staroslawska E;Yardley DA;Bachelot T;Davidson N;Wildiers H;Fasching PA;Capitain O;Ramos M;Greil R;Cognetti F;Fountzilas G;Blasinska-Morawiec M;Liedtke C;Kreienberg R;Miller WH;Tassell V;Huang X;Paolini J;Kern KA;Romieu G (2013) 'Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer'. Journal of Clinical Oncology, 31 (23):2870-2878. [DOI] [Details]
Crown J, Kennedy MJ;Tresca P;Marty M;Espie M;Burris HA;DeSilvio M;Lau MR;Kothari D;Koch KM;Di¿¿ras V (2013) 'Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer'. Annals of Oncology, 24 (8):2005-2011. [DOI] [Details]
Sclafani F, Gullo G;Sheahan K;Crown J (2013) 'BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications'. Critical Reviews in Oncology/Hematology, 87 (1):55-68. [DOI] [Details]
O'Neill F, Madden SF;Clynes M;Crown J;Doolan P;Aherne ST;O'Connor R (2013) 'A gene expression profile indicative of early stage HER2 targeted therapy response'. Molecular Cancer, 12 . [DOI] [Details]
Pierce A, McGowan PM;Cotter M;Mullooly M;O'Donovan N;Rani S;O'Driscoll L;Crown J;Duffy MJ (2013) 'Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines'. Cancer Biology and Therapy, 14 (6):537-545. [DOI] [Details]
Walsh N, Kennedy S;Larkin A;Corkery B;O'Driscoll L;Clynes M;Crown J;O'Donovan N (2013) 'EGFR and HER2 inhibition in pancreatic cancer'. Investigational New Drugs, 31 (3):558-566. [DOI] [Details]
O'Brien K, Rani S;Corcoran C;Wallace R;Hughes L;Friel AM;McDonnell S;Crown J;Radomski MW;O'Driscoll L (2013) 'Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells'. European journal of Cancer, 49 (8):1845-1859. [DOI] [Details]
Duffy MJ, McGowan PM, Crown J (2012) 'Targeted therapy for triple-negative breast cancer: Where are we?'. International Journal of Cancer, 131 (11):2471-2477. [DOI] [Details]
Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O'Driscoll L (2012) 'Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes'. PLoS ONE, 7 (12). [DOI] [Details]
Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N (2012) 'Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours'. Breast Cancer Research and Treatment, . [DOI] [Details]
Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) 'Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines'. Annals of Oncology, 23 (7):1788-1795. [DOI] [Details]
McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ (2012) 'ADAM-17: a novel therapeutic target for triple negative breast cancer'. Annals of Oncology, . [DOI] [Details]
Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM (2011) 'The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?'. Proteomics, 8 (1). [DOI] [Details]
Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ (2011) 'Src: a potential target for the treatment of triple-negative breast cancer'. Annals of Oncology, 22 (10):2234-2240. [DOI] [Details]
McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ (2011) 'The role of S100 genes in breast cancer progression'. Tumour Biology, 32 (3):441-450. [DOI] [Details]
Duffy MJ, O'Donovan N, Crown J; (2010) 'Use of molecular markers for predicting therapy response in cancer patients'. Cancer Treatment Reviews, . [DOI] [Details]
O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ; (2010) 'Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib'. MOL CANCER, 9 (6):1489-1502. [DOI] [Details]
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N; (2010) 'Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells'. Annals of Oncology, . [DOI] [Details]
Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L; (2010) 'Intracellular and Extracellular MicroRNAs in Breast Cancer'. Clinical Chemistry, . [DOI] [Details]
O'Donovan N, Browne BC, O'Brien N, Duffy MJ, Crown J, ; (2009) 'HER-2 signaling and inhibition in breast cancer'. Current Cancer Drug Targets, 3 (NA):419-438. [Details]
Doolan P, Clynes M, Kennedy S, Mehta JP, Germano S, Ehrhardt C, Crown J, O'Driscoll L (2009) 'TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer'. Tumour Biology, 30 (4):200-209. [DOI] [Details]
Corkery, B.,Crown, J.,Roche, S.,O'Connor, R.,Tryfanopoulos, D.,Clynes, M.,O'Donovan, N.; (2009) 'Constitutive Activation of Src Kinase as a Mechanism of Acquired Resistance to Dasatinib in Triple Negative Breast Cancer'. Cancer Research, 69 (24):787s-787s. Available Online [Details]
Qadir, Z.,Crown, J.,Jensen, M. R.,Clynes, M.,Slamon, D.,O'Donovan, N.; (2009) 'Combining HSP90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer'. Cancer Research, 69 (24):783s-783s. Available Online [Details]
Hurvitz, S. A.,Betting, D.,Stern, H. M.,Quinaux, E.,Stinson, J.,Seshagiri, S.,Zhao, Y.,Buyse, M.,Mackey, J.,Robert, N. J.,Valero, V.,Crown, J.,Driga, A.,Bee, V.,Slamon, D. J.,Timmerman, J. M.; (2009) 'Analysis of Fc gamma Receptor IIA & IIIA Polymorphisms: Correlation with Outcome in Trastuzumab-Treated HER2/Neu Amplified Early and Metastatic Breast Cancer Patients'. Cancer Research, 69 (24):500s-501s. Available Online [Details]
Slamon, D.,Eiermann, W.,Robert, N.,Pienkowski, T.,Martin, M.,Rolski, J.,Chan, A.,Mackey, J.,Liu, M.,Pinter, T.,Valero, V.,Falkson, C.,Fornander, T.,Shiftan, T.,Olsen, S.,Buyse, M.,Kiskartalyi, T.,Landreau, V.,Wilson, V.,Press, M.,Crown, J.,BCIRG006 Investigators; (2009) 'Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study'. Cancer Research, 69 (24):500s-500s. Available Online [Details]
Mackey, J.,Hurvitz, S.,Crown, J.,Forbes, J.,Roche, H.,Pinter, T.,Eiermann, W.,Kennedy, M. J.,Priou, F.,Provencher, L.,Adrover, E.,Pienkowski, T.,Houe, V.,Rupin, M.,Martin, M.; (2009) 'CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)'. Cancer Research, 69 (24):497s-498s. Available Online [Details]
Wardley, A. M.,McCaffrey, J.,Crown, J.,Stein, R.,Malik, Z.,Rea, D.,Barrett-Lee, P.,Lee, G.; (2009) 'Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class I Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy'. Cancer Research, 69 (24):860s-860s. Available Online [Details]
Walsh, N.,Clynes, M.,Crown, J.,O'Donovan, N.; (2009) 'Alterations in integrin expression modulates invasion of pancreatic cancer cells'. Journal of Experimental & Clinical Cancer Research, 28 . Available Online [Details]
McGowan, P. M.,McDermott, E.,Evoy, D.,Niall, O.,Crown, J.,Duffy, M. J.; (2009) 'ADAM-10 and ADAM-17 play distinct roles in breast cancer progression'. Clinical & Experimental Metastasis, 26 (7):876-876. Available Online [Details]
Crown, J.,Casey, M. A.,Cameron, D.,Newstat, B.,Stein, S. H.; (2009) 'Lapatinib (L) plus capecitabine (C) in HER2+metastatic breast cancer (MBC): exploratory analyses by prior therapy'. Ejc Supplements, 7 (2):285-285. Available Online [Details]
Eiermann, W.,Pienkowski, T.,Crown, J.,Chap, L.,Pawlicki, M.,Martin, M.,Saleh, M.,Sehdev, S.,Provencher, L.,Von Minckwitz, G.,Semiglazov, V.,Slamon, D.,Tabah-Fish, I.,Buyse, M.,Riva, A.,Taupin, H.,Sauter, G.,Mackey, J.,BCIRG005 Investigators; (2009) 'BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) in women with Her-2/neu negative axillary lymph node positive early breast cancer'. Cancer Research, 69 (2):82s-82s. Available Online [Details]
Corkery, B.,Crown, J.,Clynes, M.,O'Donovan, N.; (2009) 'Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer'. Annals of Oncology, 20 (5):862-867. Available Online [Details]
Tryfonopoulos, D.,O'Donovan, N.,Corkery, B.,Collins, D.,Clynes, M.,Crown, J.; (2009) 'Dasatinib Improves Response to Chemotherapy in Triple Negative Breast Cancer Cells'. Annals of Oncology, 20 :43-43. Available Online [Details]
McGowan, P. M., McKiernan, E., Bolster, F., Ryan, B. M., Hill, A. D. K., McDermott, E. W., Evoy, D., O'Higgins, N., Crown, J., Duffy, M. J., ; (2008) 'ADAM-17 predicts adverse outcome in patients with breast cancer'. Annals of Oncology, 19 (6):1075-1081. [Details]
Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L (2008) 'Prevalence and prognostic and predictive relevance of PRAME in breast cancer'. Breast Cancer Research and Treatment, 109 (2):359-365. [DOI] [Details]
McKiernan, E.,O'Brien, K.,Grebenchtchikov, N.,Geurts-Moespot, A.,Sieuwerts, A. M.,Martens, J. W. M.,Magdolen, V.,Evoy, D.,McDermott, E.,Crown, J.,Sweep, F. C. G. J.,Duffy, M. J.; (2008) 'Protein kinase C delta expression in breast cancer as measured by real-time PCR, western blotting and ELISA'. British Journal of Cancer, 99 (10):1644-1650. Available Online [Details]
Corkery, B.,O'Donovan, N.,Clynes, M.,Crown, J.; (2008) 'Gefitinib (G) Potentiates the Activity of Carboplatin (P) and Docetaxel (D) in Triple Negative Breast Cancer (Tnbc)'. Annals of Oncology, 19 :52-52. Available Online [Details]
Browne, B.,Crown, J.,Clynes, M.,Duffy, M. J.,Slamon, D.,O'Donovan, N.; (2008) 'Alternative Receptor Tyrosine Kinase Signalling in Trastuzumab Resistant Her-2 Positive Breast Cancer Cells'. Annals of Oncology, 19 :47-48. Available Online [Details]
Cameron, D.,Casey, M.,Press, M.,Lindquist, D.,Pienkowski, T.,Romieu, C. G.,Chan, S.,Jagiello-Gruszfeld, A.,Kaufman, B.,Crown, J.,Chan, A.,Campone, M.,Viens, P.,Davidson, N.,Gorbounova, V.,Raats, J. I.,Skarlos, D.,Newstat, B.,Roychowdhury, D.,Paoletti, P.,Oliva, C.,Rubin, S.,Stein, S.,Geyer, C. E.; (2008) 'A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses'. Breast Cancer Research and Treatment, 112 (3):533-543. Available Online [Details]
Eustace, A. J.,Crown, J.,Clynes, M.,O'Donovan, N.; (2008) 'Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines'. Journal of Translational Medicine, 6 . Available Online [Details]
Tryfonoooulos, D.,Corkery, B.,O'Donovan, N.,Clynes, M.,Crown, J.; (2008) 'Possible targets for dasatinib sensitivity in triple negative breast cancer'. Ejc Supplements, 6 (7):220-220. Available Online [Details]
Crown, J.,Burris, H. A.,Di Leo, A.,Jagiello-Gruszfeld, A.,Jones, S.,LoRussos, P.,Oliva, C.,Parikh, R.,Stein, S.,Koehler, M.; (2008) 'Tolerability of lapatinib in combination with taxanes (T) in 507 patients with breast cancer (BC)'. Ejc Supplements, 6 (7):200-200. Available Online [Details]
De Azambuja, E.,McCaskill-Stevens, W.,Quinaux, E.,Buyse, M.,Crown, J.,Francis, P.,Gelber, R.,Piccart-Gebhart, M.; (2008) 'The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial'. Ejc Supplements, 6 (7):58-59. Available Online [Details]
Martinez, V.,Kennedy, S.,Doolan, P.,Gammell, P.,Joyce, H.,Kenny, E.,Mehta, J. P.,Ryan, E.,O'Connor, R.,Crown, J.,Clynes, M.,O'Driscoll, L.; (2008) 'Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue'. Breast Cancer Research and Treatment, 110 (3):521-530. Available Online [Details]
Francis, P.,Crown, J.,Di Leo, A.,Buyse, M.,Balil, A.,Andersson, M.,Nordenskjold, B.,Lang, I.,Jakesz, R.,Vorobiof, D.,Gutierrez, J.,van Hazel, G.,Dolci, S.,Jamin, S.,Bendahmane, B.,Gelber, R. D.,Goldhirsch, A.,Castiglione-Gertsch, M.,Piccart-Gebhart, M.,BIG 02-98 Collaborat Grp; (2008) 'Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial'. Journal of the National Cancer Institute, 100 (2):121-133. Available Online [Details]
Kennedy, S.,Clynes, M.,Doolan, P.,Mehta, J. P.,Rani, S.,Crown, J.,O'Driscoll, L.; (2008) 'SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue'. British Journal of Cancer, 98 (10):1641-1645. Available Online [Details]
Crown J, Duffy MJ, ; (2008) 'A personalized approach to cancer treatment: how biomarkers can help'. Clinical Chemistry, 11 (NA):1770-1779. [DOI] [Details]
O'Connor, R.,O'Leary, M.,Ballot, J.,Collins, C. D.,Kinsella, P.,Mager, D. E.,Arnold, R. D.,O'Driscoll, L.,Larkin, A.,Kennedy, S.,Fennelly, D.,Clynes, M.,Crown, J.; (2007) 'A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer'. Cancer Chemotherapy and Pharmacology, 59 (1):79-87. Available Online [Details]
Slamon, D. J.,Mackey, J.,Robert, N.,Crown, J.,Martin, M.,Eiremann, W.,Pienkowski, T.,Bee, V.,Taupin, H.,Villalobos, I.,Lindsay, M. A.,Riva, A.,Hurvitz, S.,Glaspy, J.,Pauletti, G.,Sauter, G.,Press, M.; (2007) 'Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease'. Breast Cancer Research and Treatment, 106 :S5-S6. Available Online [Details]
Browne, B. C.,Crown, J.,Venkatesan, N.,Pegram, M.,Clynes, M.,Duffy, M. J.,Slamon, D. J.,O'Donovan, N.; (2007) 'Insulin-like growth factor I receptor (IGF-IR) inhibition enhances response to trastuzumab in HER2-overexpressing breast cancer cells'. Molecular Cancer Therapeutics, 6 (12):3551s-3551s. Available Online [Details]
O'Driscoll, L.,Walsh, N.,Larkin, A.,Ballot, J.,Ooi, W. S.,Gullo, G.,O'Connor, R.,Clynes, M.,Crown, J.,Kennedy, S.; (2007) 'MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma'. Anticancer Research, 27 (4B):2115-2120. Available Online [Details]
Dowling, P.,O'Driscoll, L.,Meleady, P.,Henry, M.,Roy, S.,Ballot, J.,Moriarty, M.,Crown, J.,Clynes, M.; (2007) '2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins'. Electrophoresis, 28 (23):4302-4310. Available Online [Details]
Crown, J.,Cameron, D.,Martin, A. M.,Newstat, B.,Pienkowski, T.,Jagiello-Gruszfeld, A.,Kaufman, B.,Casey, M. A.,Stein, S.,Geyer, C.; (2007) 'Lapatinib (L) plus Capecitabine (C) in HER2+ advanced breast cancer (ABC): report of updated efficacy and gene-array data'. Ejc Supplements, 5 (4):212-212. Available Online [Details]
Corkery, B.,O'Donovan, N.,Clynes, M.,Crown, J.; (2007) 'Gefitinib enhances response to chemotherapy in triple-negative Breast Cancer (BrCa)'. Ejc Supplements, 5 (4):185-185. Available Online [Details]
Au, H. J.,Robert, N.,Eiermann, W.,Pienkowski, T.,Crown, J.,Martin, M.,Pawlicki, M.,Chan, A.,Bee, V.,Slamon, D.; (2007) 'BCIRG 006: quality of life (QoL) of patients (pts) treated with docetaxel and trastuzumab-based regimens in node positive and high risk node negative HER2 positive early breast cancer'. Breast Cancer Research and Treatment, 106 :S147-S147. Available Online [Details]
Geyer, C. E.,Forster, J.,Lindquist, D.,Chan, S.,Romieu, C. G.,Pienkowski, T.,Jagiello-Gruszfeld, A.,Crown, J.,Chan, A.,Kaufman, B.,Skarlos, D.,Campone, M.,Davidson, N.,Berger, M.,Oliva, C.,Rubin, S. D.,Stein, S.,Cameron, D.; (2007) 'Lapatinib plus capecitabine for HER2-positive advanced breast cancer (vol 355, pg 2733, 2006)'. New England Journal of Medicine, 356 (14):1487-1487. Available Online [Details]
Browne, B.,O'Donovan, N.,Venkatesan, N.,Pegram, M.,Clynes, M.,Duffy, M. J.,Crown, J.,Slamon, D. J.; (2007) 'The role of insulin-like growth factor I receptor (IGF-IR) in trastuzumab resistance in breast cancer cells'. Anticancer Research, 27 (3A):1379-1379. Available Online [Details]
O'Donovan, N.,Browne, B.,Crown, J.,Duffy, M. J.,Slamon, D.,Clynes, M.; (2007) 'EGFR and HER-2 antagonists in breast cancer'. Anticancer Research, 27 (3A):1374-1374. Available Online [Details]
Roy, S.,Kenny, E.,Kennedy, S.,Larkin, A.,Ballot, J.,De Villarreal, M. P.,Crown, J.,O'Driscoll, L.; (2007) 'MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer'. Anticancer Research, 27 (3A):1325-1330. Available Online [Details]
O'Donovan, N.,Crown, J.; (2007) 'EGFR and HER-2 antagonists in breast cancer'. Anticancer Research, 27 (3A):1285-1294. Available Online [Details]
Wall, R.,McMahon, G.,Crown, J.,Clynes, M.,O'Connor, R.; (2007) 'Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples'. Talanta, 72 (1):145-154. Available Online [Details]
Crown, J.; (2006) 'Maximising outcomes in adjuvant breast cancer'. Ejc Supplements, 4 (5):21-24. Available Online [Details]
Pienkowski, T.,Forbes, J.,Valero, V.,Eiermann, W.,Von Minckwitz, G.,Martin, M.,Smylie, M.,Crown, J.,Noel, N.,Pegram, M.; (2006) 'BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)'. Annals of Oncology, 17 :71-71. Available Online [Details]
Cameron, D. A.,Geyer, C. E.,Chan, D. S.,Pienkowski, T.,Romieu, C. G.,Jagiello-Gruszfeld, A.,Crown, J.,Oliva, C.,Newstat, B.,Bailey-Tippets, M.; (2006) 'Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+advanced or metastatic breast cancer (MBC) patients (PTS) pretreated with chemotherapy and trastuzumab'. Annals of Oncology, 17 :69-70. Available Online [Details]
Crown, J.,Piccart-Gebhart, M.; (2006) 'Road map to interpreting breast cancer data in 2006 and beyond - Based on Proceedings from the Lilly Oncology Satellite Symposium held at the 5th European Breast Cancer Conference - 21st March 2006, Nice, France - Introduction'. Ejc Supplements, 4 (13):1-1. Available Online [Details]
O'Donovan, N.,Clynes, M.,Crown, J.; (2006) 'Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines'. Breast Cancer Research and Treatment, 100 :S105-S105. Available Online [Details]
Malinovszky, K. M.,Gould, A.,Foster, E.,Cameron, D.,Humphreys, A.,Crown, J.,Leonard, R. C. F.,Anglo Celtic Co operative Oncology; (2006) 'Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer'. British Journal of Cancer, 95 (12):1626-1631. Available Online [Details]
Geyer, C. E.,Forster, J.,Lindquist, D.,Chan, S.,Romieu, C. G.,Pienkowski, T.,Jagiello-Gruszfeld, A.,Crown, J.,Chan, A.,Kaufman, B.,Skarlos, D.,Campone, M.,Davidson, N.,Berger, M.,Oliva, C.,Rubin, S. D.,Stein, S.,Cameron, D.; (2006) 'Lapatinib plus capecitabine for HER2-positive advanced breast cancer'. New England Journal of Medicine, 355 (26):2733-2743. Available Online [Details]
Crown, J.; (2006) 'Metastatic breast cancer: why are we here and where are we going?'. Ejc Supplements, 4 (13):2-5. Available Online [Details]
Ryan, B. M.,Konecny, G. E.,Kahlert, S.,Wang, H. J.,Untch, M.,Meng, G.,Pegram, M. D.,Podratz, K. C.,Crown, J.,Slamon, D. J.,Duffy, M. J.; (2006) 'Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1'. Annals of Oncology, 17 (4):597-604. Available Online [Details]
Eiermann, W.,Pienkowski, T.,Crown, J.,Chap, L.,Pawlicki, M.,Martin, M.,Chan, A.,Saleh, M.,Sehdev, S.,Provencher, L.,Von Minckwitz, G.,Semiglazov, V.,Slamon, D.,Tabah-Fisch, I.,Buyse, M.,Riva, A.,Taupin, H.,Sauter, G.,Mackey, J.,BCIRG 005 Investigators; (2005) 'Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study'. Breast Cancer Research and Treatment, 94 :S62-S63. Available Online [Details]
O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M (2005) 'Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy'. Urology, 65 (2):331-332. [DOI] [Details]
Ryan, B.,O'Donovan, N.,Browne, B.,O'Shea, C.,Crown, J.,Hill, A. D. K.,McDermott, E.,O'Higgins, N.,Duffy, M. J.; (2005) 'Expression of survivin and its splice variants survivin-2B and survivin-Delta Ex3 in breast cancer'. British Journal of Cancer, 92 (1):120-124. Available Online [Details]
Slamon, D.,Eiermann, W.,Robert, N.,Pienkowski, T.,Martin, M.,Pawlicki, M.,Chan, M.,Buyse, M.,Bee, V.,Crown, J.; (2005) 'BCIRG 006: Superior cardiac safety of adjuvant docetaxel (T), carboplatin (C) and trastuzumab (H) compared to doxorubicin (A) and cyclophosphamide (Cyc) followed by TH in patients with early stage breast cancer and altered HER2 gene'. Ejc Supplements, 3 (2):74-74. Available Online [Details]
Press, M. F.,Bernstein, L.,Sauter, G.,Zhou, J. Y.,Eiermann, W.,Pienkowski, T.,Crown, J.,Robert, N.,Bee, V.,Taupin, H.,Villalobos, I.,Seelig, S.,Pegram, M.,Slamon, D. J.; (2005) 'Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting'. Breast Cancer Research and Treatment, 94 :S54-S54. Available Online [Details]
Slamon, D.,Eiermann, W.,Robert, N.,Pienkowski, T.,Martin, M.,Pawlicki, M.,Chan, A.,Smylie, M.,Liu, M.,Falkson, C.,Pinter, T.,Fornander, T.,Shiftan, T.,Valero, V.,Von Minckwitz, G.,Mackey, J.,Tabah-Fisch, J.,Buyse, M.,Lindsay, M. A.,Riva, A.,Bee, V.,Pegram, M.,Press, M.,Crown, J.,BCIRG 006 Investigators; (2005) 'Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study'. Breast Cancer Research and Treatment, 94 :S5-S5. Available Online [Details]
Evans, T. R. J.,Yellowlees, A.,Foster, E.,Earl, H.,Cameron, D. A.,Hutcheon, A. W.,Coleman, R. E.,Perren, T.,Gallagher, C. J.,Quigley, M.,Crown, J.,Jones, A. L.,Highley, M.,Robert, L. M. H.,Mansi, J. L.; (2005) 'Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study'. Journal of Clinical Oncology, 23 (13):2988-2995. Available Online [Details]
Power, R. E.,Kennedy, J.,Crown, J.,Fraser, I.,Thornhill, J. A.; (2005) 'Pelvic recurrence in stage I seminoma: A new phenomenon that questions modern protocols for radiotherapy and follow-up'. International Journal of Urology, 12 (4):378-382. Available Online [Details]
Ballot, J.,Doran, Z.,Leyvraz, S.,Verrill, M.,Guillem, V.,Efremidis, A.,Bru, J. G. C.,Welch, R.,Montes, A.,Rapoport, B.,Cameron, D.,Leonard, R.,Baselga, J.,Crown, J.; (2005) 'Externally audited results of the international breast cancer dose-intensity study (IBDIS)'. Bone Marrow Transplantation, 35 :S51-S52. Available Online [Details]
Ryan, B.,Konecny, G.,Kahlert, S.,Wang, H.,Crown, J.,Untch, M.,Pegram, M.,Slamon, D. J.,Duffy, M. J.; (2005) 'Survivin protein expression predicts poor outcome in patients with primary breast cancer'. Journal of Clinical Oncology, 23 (16):15s-15s. Available Online [Details]
Martin, M.,Vogel, C.,Crown, J.,Mackey, J.,Bcirg; (2005) 'Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer'. Jama-Journal of the American Medical Association, 294 (17):2166-2166. Available Online [Details]
Evans, T. R. J.,Yellowlees, A.,Foster, E.,Earl, H.,Cameron, D. A.,Hutcheon, A. W.,Coleman, R. E.,Crown, J.,Leonard, R. C.,Mansi, J. L.; (2004) 'Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer'. Journal of Clinical Oncology, 22 (14):8S-8S. Available Online [Details]
Duffy, M. J.,Duggan, C.,Keane, R.,Hill, A. D. K.,McDermott, E.,Crown, J.,O'Higgins, N.; (2004) 'High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer'. Clinical Chemistry, 50 (3):559-563. Available Online [Details]
Pegram, M. D.,Pienkowski, T.,Northfelt, D. W.,Eiermann, W.,Patel, R.,Fumoleau, P.,Quan, E.,Crown, J.,Toppmeyer, D.,Smylie, M.,Riva, A.,Blitz, S.,Press, M. F.,Reese, D.,Lindsay, M. A.,Slamon, D. J.; (2004) 'Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer'. Journal of the National Cancer Institute, 96 (10):759-769. Available Online [Details]
Crown, J.,O'Leary, M.,Ooi, W. S.; (2004) 'Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience'. Oncologist, 9 :24-32. Available Online [Details]
Leonard, R. C. F.,Lind, M.,Twelves, C.,Coleman, R.,van Belle, S.,Wilson, C.,Ledermann, J.,Kennedy, I.,Barrett-Lee, P.,Perren, T.,Verrill, M.,Cameron, D.,Foster, E.,Yellowlees, A.,Crown, J.,Anglo-Celtic Cooperative Oncology; (2004) 'Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial'. Journal of the National Cancer Institute, 96 (14):1076-1083. Available Online [Details]
Di Leo, A.,Chan, S.,Paesmans, M.,Friedrichs, K.,Pinter, T.,Cocquyt, V.,Murray, E.,Bodrogi, I.,Walpole, E.,Lesperance, B.,Korec, S.,Crown, J.,Simmonds, P.,Von Minckwitz, G.,Leroy, J. Y.,Durbecq, V.,Isola, J.,Aapro, M.,Piccart, M. J.,Larsimont, D.; (2004) 'HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel'. Breast Cancer Research and Treatment, 86 (3):197-206. Available Online [Details]
Crown, J.; (2004) 'Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer'. Lancet, 364 (9442):1299-1300. Available Online [Details]
Larkin, A.,O'Driscoll, L.,Kennedy, S.,Purcell, R.,Moran, E.,Crown, J.,Parkinson, M.,Clynes, M.; (2004) 'Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study'. International Journal of Cancer, 112 (2):286-294. Available Online [Details]
Dillon, M. F.,Hill, A. D. K.,Quinn, C. M.,O'Doherty, A.,Crown, J.,Fleming, F. J.,McDermott, E. W.,O'Higgins, N.; (2004) 'Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer'. Journal of Medical Screening, 11 (3):130-134. Available Online [Details]
Durbecq, V.,Paesmans, M.,Cardoso, F.,Desmedt, C.,Di Leo, A.,Chan, S.,Friedrich, K.,Pinter, T.,Van Belle, S.,Murray, E.,Bodrogi, I.,Walpole, E.,Lesperance, B.,Korec, S.,Crown, J.,Simmonds, P.,Perren, T. J.,Leroy, J. Y.,Rouas, G.,Sotiriou, C.,Piccart, M.,Larsimont, D.; (2004) 'Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel'. Molecular Cancer Therapeutics, 3 (10):1207-1214. Available Online [Details]
O'Leary, M.,O'Connor, R.,Roy, S.,Ballot, J.,Ooi, W.,Fennelly, D.,Sheehan, L.,Collins, C.,Clynes, M.,Crown, J.; (2004) 'Phase I trial of the multi-drug resistance (MDR) protein-1 (MRP-1) modulating agent sulindac (S) plus epirubicin (E) in patients (pts) with advanced cancer'. Journal of Clinical Oncology, 22 (14):159s-159s. Available Online [Details]
Slamon, D.,Yeon, C. H.,Pienkowski, T.,Northfelt, D.,Eiermann, W.,Patel, R.,Crown, J.,Riva, A.,Blitz, S.,Pegram, M.; (2004) 'Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+advanced breast cancer (ABC)'. Journal of Clinical Oncology, 22 (14):37s-37s. Available Online [Details]
Crown, J.,Leyvraz, S.,Perey, L.,Verrill, M.,Guillem, V.,Efremidis, A.,Garcia-Conde, B. J.,Welch, R.,Montes, A.,Piazza, E.,Rappaport, B.,Pienkowski, T.,Skotnicki, A.,Cameron, D.,Vahdat, L.,Bobev, D. G.,Bertelli, G.,Leonard, R.,Baselga, B.; (2003) 'Up front tandem high-dose chemotherapy compared to standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: the International Randomized Breast Cancer Dose Intensity Study'. Breast Cancer Research and Treatment, 82 :S152-S152. Available Online [Details]
O'Donovan, N.,Crown, J.,Stunell, H.,Hill, A. D. K.,McDermott, E.,O'Higgins, N.,Duffy, M. J.; (2003) 'Caspase 3 in breast cancer'. Clinical Cancer Research, 9 (2):738-742. Available Online [Details]
Ballot, J.,McDonnell, D.,Crown, J.; (2003) 'Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel'. Journal of the National Cancer Institute, 95 (11):831-832. Available Online [Details]
Crown, J.,Pegram, M.; (2003) 'Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy'. Breast Cancer Research and Treatment, 79 :S11-S18. Available Online [Details]
Crown, J.; (2003) 'Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?'. Lancet, 362 (9385):677-678. Available Online [Details]
Cameron, D. A.,Anderson, A.,Toy, E.,Evans, T. R. J.,Le Vay, J. H.,Kennedy, I. C. S.,Grieve, R. J.,Perren, T. J.,Jones, A.,Mansi, J.,Crown, J.,Leonard, R. C. F.; (2002) 'Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?'. British Journal of Cancer, 87 (12):1365-1369. Available Online [Details]
Rosti, G.,Ferrante, P.,Ledermann, J.,Leyvraz, S.,Ladenstein, R.,Koscileniak, E.,Crown, J.,Dazzi, C.,Cariello, A.,Marangolo, M.; (2002) 'High-dose chemotherapy for solid tumors: results of the EBMT'. Critical Reviews in Oncology Hematology, 41 (2):129-140. Available Online [Details]
Ryan, B.,O'Shea, C.,O'Donovan, N.,Kennedy, S.,Crown, J.,McDermott, E.,Hill, A. D. K.,O'Higgins, N.,Duffy, M. J.; (2002) 'Survivin mRNA and protein in breast cancer'. British Journal of Cancer, 86 :S87-S87. Available Online [Details]
Fabiano, A.,Filho, F.,Crown, J.,Cardoso, F.,Nogaret, J. M.,Duffy, K.,Dolci, S.,Rowan, S.,O'Higgins, N.,Batter, V.,Paesmans, M.,Piccart, M. J.,Di Leo, A.; (2002) '3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: A pilot study'. Anticancer Research, 22 (4):2471-2476. Available Online [Details]
Crown, J.,Dieras, V.,Kaufmann, M.,von Minckwitz, G.,Kaye, S.,Leonard, R.,Marty, M.,Misset, J. L.,Osterwalder, B.,Piccart, M.; (2002) 'Chemotherapy for metastatic breast cancer - report of a European expert panel'. Lancet Oncology, 3 (12):719-727. Available Online [Details]
Leonard, R. C. F.,Toy, E.,Evans, T.,Levay, J.,Kennedy, I.,Grieve, R.,Perren, T.,Jones, A.,Mansi, J.,Crown, J.,McIntyre, G.,Anderson, A.,Povey, S.,Cameron, D.; (2001) 'Adriamycin/CMF (A/CMF) for high risk breast cancer in the UK is as good as (CALGB9344) AC/taxol)-Anglo-Celtic Cooperative Oncology Group (ACCOG)'. British Journal of Cancer, 85 :20-20. Available Online [Details]
Huober, J.,Crown, J.; (2001) 'New aspects in adjuvant therapy for breast cancer - Interview with John Crown'. Geburtshilfe Und Frauenheilkunde, 61 (8):637-638. Available Online [Details]
Crown, J.; (2001) 'A "bureausceptic" view of cancer drug rationing'. Lancet, 358 (9294):1660-1660. Available Online [Details]
Crown, J.; (2001) 'Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer'. Oncologist, 6 :17-21. Available Online [Details]
Crown, J.; (2001) 'Docetaxel: Overview of an active drug for breast cancer'. Oncologist, 6 :1-4. Available Online [Details]
Cardoso, F.,Ferreira, A. F.,Crown, J.,Dolci, S.,Paesmans, M.,Riva, A.,Di Leo, A.,Piccart, M. J.; (2001) 'Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study'. Anticancer Research, 21 (1B):789-795. Available Online [Details]
Crown, J.,Fennelly, D.,Collins, C.,Jones, M.,Ennis, S.,Rowan, S.,Flynn, C.,Nutty, S.,Armstrong, J.,Moulton, B.; (2000) 'Mature results of a phase I/II evaluation of docetaxel (T), ifosphamide (I), cisplatin (C) supported by lenograstim (L) in patients (pts) with advanced non-small cell lung cancer (NSCLCa): An Irish Clinical Oncology Research Group (ICORG) study'. Annals of Oncology, 11 :118-119. Available Online [Details]
Crown, J.; (2000) 'Docetaxel: Efficacy in first- and second-line therapy of advanced breast cancer'. Onkologie, 23 :1-3. Available Online [Details]
Crown, J.,O'Leary, M.; (2000) 'Taxanes as adjuvant for breast cancer - Reply'. Lancet, 356 (9228):508-508. Available Online [Details]
Crown, J.; (2000) 'Breast-cancer treatment put into question'. Lancet, 355 (9217):1828-1829. Available Online [Details]
Crown, J.,O'Leary, M.; (2000) 'The taxanes: an update'. Lancet, 355 (9210):1176-1178. Available Online [Details]
Di Leo, A.,Crown, J.,Nogaret, J. M.,Duffy, K.,Bartholomeus, S.,Dolci, S.,Rowan, S.,O'Higgins, N.,Paesmans, M.,Larsimont, D.,Riva, A.,Piccart, M. J.; (2000) 'A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer'. Annals of Oncology, 11 (2):169-175. Available Online [Details]
Crown, J.; (1999) 'Taxoid therapy of breast cancer'. Onkologie, 22 :29-30. Available Online [Details]
Crown, J.,Chan, K. M.,O'Leary, M.,Ballot, J.,King, T.,Murphy, J.,Lenehan, P.,Drumm, J.,McCarthy, D.,Fennelly, D.; (1999) 'Feasibility of an accelerated multi-cycle high-dose chemotherapy regimen including high-dose thiotepa for patients (Pts) with poor risk ovarian cancer (OC)'. European Journal of Cancer, 35 :S232-S232. Available Online [Details]
Crown, J.,Coiffier, B.,Cortes-Funes, H.,Guillaume, T.,Kanz, L.,Kvalheim, G.,Marty, M.,Symann, M.; (1999) 'ESTIC position paper: High-dose chemotherapy for breast cancer, investigation should continue'. Annals of Oncology, 10 (8):903-905. Available Online [Details]
Chan, S.,Friedrichs, K.,Noel, D.,Pinter, T.,Van Belle, S.,Vorobiof, D.,Duarte, R.,Gil, M. G.,Bodrogi, I.,Murray, E.,Yelle, L.,von Minckwitz, G.,Korec, S.,Simmonds, P.,Buzzi, F.,Mancha, R. G.,Richardson, G.,Walpole, E.,Ronzoni, M.,Murawsky, M.,Alakl, M.,Riva, A.,Crown, J.,303 Study Grp; (1999) 'Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer'. Journal of Clinical Oncology, 17 (8):2341-2354. Available Online [Details]
Crown, J.; (1999) 'Phase III randomized trials of docetaxel in patients with metastatic breast cancer'. Seminars in Oncology, 26 (3):33-38. Available Online [Details]
Breathnach, O.,Donnellan, P.,Collins, D.,McNicholas, W.,Crown, J.; (1999) 'Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: Case report and review of the literature'. Annals of Oncology, 10 (4):461-465. Available Online [Details]
Hudis, C.,Fornier, M.,Riccio, L.,Lebwohl, D.,Crown, J.,Gilewski, T.,Surbone, A.,Currie, V.,Seidman, A.,Reichman, B.,Moynahan, M.,Raptis, G.,Sklarin, N.,Theodoulou, M.,Weiselberg, L.,Salvaggio, R.,Panageas, K. S.,Yao, T. J.,Norton, L.; (1999) '5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study'. Journal of Clinical Oncology, 17 (4):1118-1126. Available Online [Details]
Crown, J.; (1999) 'A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer'. Seminars in Oncology, 26 (1):5-9. Available Online [Details]
Crown, J.; (1998) 'Evolution in the treatment of advanced breast cancer'. Seminars in Oncology, 25 (5):12-17. Available Online [Details]
Nabholtz, J. M.,Crown, J.; (1998) 'Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: Preliminary results'. Seminars in Oncology, 25 (6):4-9. Available Online [Details]
Di Leo, A.,Crown, J.,Nogaret, L. M.,Duffy, K.,Bartholomeus, S.,Dolci, S.,Rowan, S.,O'Higgins, N.,Riva, A.,Piccart, M. J.; (1998) 'Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)'. European Journal of Cancer, 34 :S41-S41. Available Online [Details]
Cullivan, R.,Crown, J.,Walsh, N.; (1998) 'The use of psychotropic medication in patients referred to a psycho-oncology service'. Psycho-Oncology, 7 (4):301-306. Available Online [Details]
Donnellan, P.,Armstrong, J.,Rowan, S.,Fennelly, D.,Lynch, V.,McDonnell, T.,McNicholas, W.,Crown, J.; (1998) 'New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer'. Seminars in Oncology, 25 (3):20-23. Available Online [Details]
Di Leo, A.,Crown, J.,Nogaret, J. M.,Duffy, K.,Bartholomeus, S.,Rowan, S.,Dolci, S.,O'Higgins, N.,Riva, A.,Piccart, M. J.; (1998) 'Feasibility of docetaxel (D)-containing regimens in the adjuvant treatment (AT) of breast cancer (BC)'. European Journal of Cancer, 34 :S36-S36. Available Online [Details]
DiLeo, A.,Crown, J.,Nogaret, J. M.,Duffy, K.,Bartholomeus, S.,Rowan, S.,OHiggins, N.,Riva, A.,Piccart, M. J.; (1997) 'Sequential adriamycin (A), docetaxel (D) and CMF in the adjuvant treatment (AT) of breast cancer (BC)'. European Journal of Cancer, 33 :359-359. Available Online [Details]
Crown, J.; (1997) 'High-dose chemotherapy of metastatic breast cancer: The end of the beginning?'. British Journal of Cancer, 75 (4):467-469. Available Online [Details]
Maguire, T. M.,Shering, S. G.,McDermott, E. W.,OHiggins, N.,Fennelly, J. J.,Crown, J.,Duffy, M. J.; (1997) 'Assay of E-cadherin by ELISA in human breast cancers'. European Journal of Cancer, 33 (3):404-408. Available Online [Details]
Crown, J.; (1997) 'Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer'. European Journal of Cancer, 33 :S15-S19. Available Online [Details]
Crown, J.; (1996) 'High dose chemotherapy for breast cancer'. Eurocancer 96 - Proceedings of the Ninth Congress, :101-102 4. Available Online [Details]
Crown, J.; (1996) 'High-dose chemotherapy in resistant breast cancer'. Breast, 5 (4):298-303. Available Online [Details]
Crown, J.; (1996) 'Current status of high dose chemotherapy in breast cancer'. British Journal of Cancer, 74 :Sp30-Sp30. Available Online [Details]
Crown, J.; (1996) 'Current status of high-dose chemotherapy in metastatic breast cancer'. British Journal of Cancer, 73 (8):1015-1015. Available Online [Details]
Hudis, C.,Seidman, A.,Raptis, G.,Fennelly, D.,Gilewski, T.,Baselga, J.,Theodoulou, M.,Sklarin, N.,Moynahan, M.,Surbone, A.,Currie, V.,Lebwohl, D.,Uhlenhopp, M.,Crown, J.,Norton, L.; (1996) 'Sequential adjuvant therapy: The Memorial Sloan-Kettering Cancer Center experience'. Seminars in Oncology, 23 (1):58-64. Available Online [Details]
Crown, J.,Norton, L.; (1995) 'Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer'. Annals of Oncology, 6 :21-26. Available Online [Details]
Fennelly, D.,Schneider, J.,Spriggs, D.,Bengala, C.,Hakes, T.,Reich, L.,Barakat, R.,Curtin, J.,Moore, M. A. S.,Hoskins, W.,Norton, L.,Crown, J.; (1995) 'Dose-Escalation of Paclitaxel with High-Dose Cyclophosphamide, with Analysis of Progenitor-Cell Mobilization and Hematologic Support of Advanced Ovarian-Cancer Patients Receiving Rapidly Sequenced High-Dose Carboplatin Cyclophosphamide Courses'. Journal of Clinical Oncology, 13 (5):1160-1166. Available Online [Details]
Crown, J.,Hamilton, N.,Raptis, G.,Kritz, A.,Vahdat, L.,Norton, L.; (1995) 'Carboplatin and Etoposide in Metastatic Breast-Cancer'. Annals of Oncology, 6 (4):403-403. Available Online [Details]
Crown, J.,Raptis, G.,Hamilton, N.,Fennelly, D.,Vahdat, L.,Norton, L.; (1995) 'High-Dose Chemotherapy of Breast-Cancer - Current Status and Developmental Strategies'. European Journal of Cancer, 31A (5):809-811. Available Online [Details]
Vahdat, L.,Raptis, G.,Fennelly, D.,Hamilton, N.,Reich, L.,Tiersten, A.,Harrison, M.,Hudis, C.,Moore, M.,Yao, T. J.,Norton, L.,Crown, J.; (1995) 'Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer'. Clinical Cancer Research, 1 (11):1267-1273. Available Online [Details]
Duffy, M. J.,Duggan, C.,Mulcahy, H.,McDermott, E. W.,Fenelly, J. J.,Crown, J.,OHiggins, N. J.; (1995) 'Urokinase plasminogen activator, a potential prognostic marker for node-negative breast cancer'. European Journal of Cancer, 31A :662-662. Available Online [Details]
Raptis, G.,Tiersten, A.,Shapiro, F.,Schneider, J.,Hamilton, N.,Reich, L.,Wuest, D.,Gucciardo, A.,Quiguyan, L.,Gilewski, T.,Baselga, J.,Theodoulou, M.,Hudis, C.,Surbone, A.,Moore, M.,Crown, J.,Norton, L.; (1995) 'Rapid hematologic recovery following CD34+ selected versus unselected peripheral blood progenitor cell (PBPC) plus filgrastim (G) rescue of sequential high dose chemotherapy (HDC) in patients (PTS) with metastatic breast cancer (MBC)'. Blood, 86 (10):1601-1601. Available Online [Details]
Crown, J.; (1995) 'High-Dose Chemotherapy of Solid Tumors'. Annals of Oncology, 6 :11-15. Available Online [Details]
Seidman, A. D.,Tiersten, A.,Hudis, C.,Gollub, M.,Barrett, S.,Yao, T. J.,Lepore, J.,Gilewski, T.,Currie, V.,Crown, J.,Hakes, T.,Baselga, J.,Sklarin, N.,Moynihan, M. E.,Tong, W.,Egorin, M.,Kearns, C.,Spriggs, D.,Norton, L.; (1995) 'Phase-Ii Trial of Paclitaxel by 3-Hour Infusion as Initial and Salvage Chemotherapy for Metastatic Breast-Cancer'. Journal of Clinical Oncology, 13 (10):2575-2581. Available Online [Details]
Vahdat, L.,Raptis, G.,Fennelly, D.,Crown, J.; (1995) 'High-Dose Chemotherapy of Metastatic Breast-Cancer - a Review'. Cancer Investigation, 13 (5):505-510. Available Online [Details]
Oreilly, E.,Crown, J.; (1994) 'The Medical-Treatment of Advanced Prostate-Cancer'. Irish Medical Journal, 87 (5):130-132. Available Online [Details]
Toner, G. C.,Gabrilove, J. L.,Gordon, M.,Crown, J.,Jakubowski, A. A.,Meisenberg, B.,Sheridan, C.,Boone, T.,Vincent, M. E.,Markman, M.; (1994) 'Phase-I Trial of Intravenous and Intraperitoneal Administration of Granulocyte-Macrophage Colony-Stimulating Factor'. Journal of Immunotherapy, 15 (1):59-66. Available Online [Details]
Crown, J.; (1994) 'Multicycle High-Dose Chemotherapy Supported by Peripheral-Blood Progenitors in the Therapy of Solid Tumors'. Pathologie Biologie, 42 (10):974-975. Available Online [Details]
Fennelly, D.,Wasserheit, C.,Schneider, J.,Hakes, T.,Reich, L.,Curtin, J.,Yao, T. J.,Markman, M.,Norton, L.,Crown, J.; (1994) 'Simultaneous Dose-Escalation and Schedule Intensification of Carboplatin-Based Chemotherapy Using Peripheral-Blood Progenitor Cells and Filgrastim - a Phase-I Trial'. Cancer Research, 54 (23):6137-6142. Available Online [Details]
Fennelly, D.,Vahdat, L.,Schneider, J.,Reich, L.,Hamilton, N.,Hakes, T.,Raptis, G.,Wasserheit, C.,Kritz, A.,Gulati, S.,Markman, M.,Hoskins, W.,Norton, L.,Crown, J.; (1994) 'High-Intensity Chemotherapy with Peripheral-Blood Progenitor-Cell Support'. Seminars in Oncology, 21 (2):21-25. Available Online [Details]
Crown, J.,Vahdat, L.,Fennelly, D.,Francis, P.,Wasserheit, C.,Hudis, C.,Kritz, A.,Schneider, J.,Hamilton, N.,Gilewski, T.,Norton, L.; (1993) 'High-Intensity Chemotherapy with Hematopoietic Support in Breast-Cancer'. Breast Cancer: From Biology to Therapy, 698 :378-388. Available Online [Details]
Bengala, C.,Fennelly, D.,Shapiro, F.,Schneider, J.,Reich, L.,Moore, M. A. S.,Norton, L.,Crown, J.; (1993) 'Taxol (Txl) in Combination with Cyclophosphamide (Ctx) and G-Csf Can Improve the Mobilization of Peripheral-Blood Progenitors Cells (Pbpcs) in Untreated Locally Advanced Ovarian-Cancer - Preliminary-Report'. Blood, 82 (10):A82-A82. Available Online [Details]
Crown, J.,Jakubowski, A.,Gabrilove, J.; (1993) 'Interleukin-1 - Biological Effects in Human Hematopoiesis'. Leukemia & Lymphoma, 9 (6):433-440. Available Online [Details]
Crown, J.,Kritz, A.,Vahdat, L.,Reich, L.,Moore, M.,Hamilton, N.,Schneider, J.,Harrison, M.,Gilewski, T.,Hudis, C.,Gulati, S.,Norton, L.; (1993) 'Rapid Administration of Multiple Cycles of High-Dose Myelosuppressive Chemotherapy in Patients with Metastatic Breast-Cancer'. Journal of Clinical Oncology, 11 (6):1144-1149. Available Online [Details]
Crown, J.,Hakes, T.,Reichman, B.,Lebwohl, D.,Gilewski, T.,Surbone, A.,Currie, V.,Yao, T. J.,Hudis, C.,Seidman, A.,Norton, L.; (1993) 'Phase-Ii Trial of Carboplatin and Etoposide in Metastatic Breast-Cancer'. Cancer, 71 (4):1254-1257. Available Online [Details]
Crown, J.,Norton, L.; (1991) 'Adjuvant Systemic Therapy for Early Breast-Cancer'. Seminars in Surgical Oncology, 7 (5):283-290. Available Online [Details]
Crown, J.,Jakubowski, A.,Kemeny, N.,Gordon, M.,Gasparetto, C.,Wong, G.,Sheridan, C.,Toner, G.,Meisenberg, B.,Botet, J.,Applewhite, J.,Sinha, S.,Moore, M.,Kelsen, D.,Buhles, W.,Gabrilove, J.; (1991) 'A Phase-I Trial of Recombinant Human Interleukin-1-Beta Alone and in Combination with Myelosuppressive Doses of 5-Fluorouracil in Patients with Gastrointestinal Cancer'. Blood, 78 (6):1420-1427. Available Online [Details]
Crown, J.,Casper, E. S.,Botet, J.,Murray, P.,Kelsen, D. P.; (1991) 'Lack of Efficacy of High-Dose Leucovorin and Fluorouracil in Patients with Advanced Pancreatic Adenocarcinoma'. Journal of Clinical Oncology, 9 (9):1682-1686. Available Online [Details]
Crown, J.,Lipzstein, R.,Cohen, S.,Goldsmith, M.,Wisch, N.,Paciucci, P. A.,Silverman, L.,Weiner, M.,Jaffrey, I.,Norton, L.,Holland, J.; (1991) 'Chemotherapy of Metastatic Merkel Cell-Cancer'. Cancer Investigation, 9 (2):129-132. Available Online [Details]
Bruckner, H. W.,Crown, J.,Mckenna, A.,Hart, R.; (1988) 'Leucovorin and 5-Fluorouracil as a Treatment for Disseminated Cancer of the Pancreas and Unknown Primary Tumors'. Cancer Research, 48 (19):5570-5572. Available Online [Details]
Bruckner, H. W.,Crown, J.,Mckenna, A.,Hart, R.; (1986) 'High-Dose Intermittent Leucovorin and 5-Fluorouracil for Unknown Primary and Atypical Pancreatic-Cancer (Pc)'. Proceedings of the American Association for Cancer Research, 27 :183-183. Available Online [Details]
 

Conference Publications

Rani, S, O'Brien, K, McDonnell, S, Hughes, L, Friel, A. M, Radomski, M. W., Crown, J. and O'Driscoll L (2011) Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes European Journal of Cancer , pp.S143-S143 [Details]
Wilson,E., Crown, J; (2010) The information needs of young women(YW) undergoing adjuvant chemotherapy (AC) for early stage breast cancer (ESBC) regarding fertiltiy and menopause issues American Society of Clinical Oncology [Details]
Wilson,E;Crown,J; (2010) The effects of a diagnosis of early stage breast cancer (ESBC) on friendships The British Psychosocial Oncology Conference , pp.9-9 [Details]
Wilson,E., Tryfonopolous, D., Mc Donnell, D., Gullo, G., Healy, J., Carroll, G., Schofield, G., Crown, J.; (2010) Economic Impact of OncotypeDx Assay in Axillary Node Negative Breast Cancer (AxN-BC) with Positive Hormone Receptor (rec+) and Normal HER-2 (HER2-) European Society of Medical Oncology [Details]
Wilson, E., Crown, J.,; (2010) Treatment Induced Menopause: The information needs of young women diagnosed with early stage breast cancer (ESBC) Changing Health: 6th International Conference on Social Work in Health and Mental Health [Details]
R.O'Cearbhaill (1), Wilson, E (1); de Frein, A., Qadir, D., Mc Donnell, D., Crown,J.,; (2007) Estimating the real cost of adjuvant trastuzumab in patients with HER-2+ early stage breast cancer: the potential impact of reduced use of expensive oncology drugs in metastatic breast cancer American Society of Clinical Oncology [Details]
Wilson, E.,Crown, J.,Ballot, J.,McDonnell, D.,Sheehan, E.,Healy, J.; (2006) Estimating the real cost of adjuvant (A) trastuxumab (T) in patients(pts) with HER-2+(H+) early stage breast cancer (ESBC) American Society of Clinical Oncology , pp.320s-320s Available Online [Details]
Wilson, E.,Ballot, J.,Healy, J.,Mackey, J.,Martin, M.,Lindsay, M.,Crown, J.; (2005) Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC) American Society of Clinical Oncology , pp.109-109 Available Online [Details]
                                                                                         

Research

 

Research Projects

Sponsor : Science Foundation Ireland (SFI)
Title : Molecular Therapeutics for Cancer: Translational Research to Individualise Therapy with Target Agents
Start Date / End Date : 01-JAN-11 / 31-DEC-11
Sponsor : Health Research Board (HRB)
Title : Funding to ICORG Hospital Site at St Vincent's University Hospital
Start Date / End Date : 01-JUL-09 / 30-JUN-13